Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 836 of 5804
-
New drug shows promise for rare movement disorder
Disease control CompletedIn this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy after standard care may delay lung cancer return
Disease control CompletedThe main purpose of this study is to see how well the experimental drug pembrolizumab (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their disease. All patients will receive 200 mg of pembrolizumab intravenously on Day 1 of each 21-day cyc…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail aims to keep myeloma in check after transplant
Disease control OngoingThe purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen co…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Double attack: radiation plus chemo shows promise for rare lymphoma
Disease control OngoingThe goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemother…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New radiation approach aims to tame prostate cancer with fewer side effects
Disease control CompletedThis trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body. Brachytherapy is a type of radiation therapy in which radioactive material sealed in needles, seeds, wires, or …
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat leukemia
Disease control CompletedThis study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can a triple-drug attack shrink hard-to-treat breast cancer?
Disease control CompletedThe purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side effects and safety. A standard chemotherapy, gemcita…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
Disease control CompletedThis study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Blood-filtering therapy may slow lung decline in transplant patients
Disease control OngoingThe primary aims of this study is to determine the efficacy and tolerability of Extracorporeal Photopheresis (ECP) for the treatment of either Refractory Bronchiolitis Obliterans Syndrome (BOS) patients (258 at cessation of enrollment April 7, 2022) or Newly Diagnosed (22 as of e…
Phase: PHASE3 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Timing of chemo could be key in colon cancer fight
Disease control OngoingBACKGROUND: In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop distant metastasis, which ultimat…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to boost survival in kids with aggressive lymphoma
Disease control OngoingThe purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.
Phase: PHASE2, PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
HIV pill combo simplifies treatment for patients over 45
Disease control CompletedThis multicenter, international, non randomized (single arm), open, phase II trial aims to evaluate the capacity of the dual combination raltegravir/etravirine to maintain virological success in virologically suppressed HIV-1 infected patients, of at least 45 years of age, switch…
Phase: PHASE2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a simple HPV test every 5 years replace frequent pap smears?
Prevention OngoingCompass is a randomised controlled trial of primary HPV testing for cervical cancer screening in Australia. A pilot study involving 5,000 women was carried out in 2013-2014. The trial will involve recruiting 76,300 women from primary health clinics. Women aged 25-69, attending fo…
Phase: NA • Sponsor: VCS Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
Shocking news: brain zaps may ward off dementia
Prevention OngoingThis 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham ("placebo") tDCS combined with sham ("placebo") CR in slowing down cognitive …
Phase: NA • Sponsor: Centre for Addiction and Mental Health • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
Can chemo before surgery stop prostate cancer from spreading?
Disease control Recruiting nowCurrent agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Immune cells Re-Trained to fight Drug-Resistant ovarian cancer
Disease control OngoingThis is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating lymphocytes (TILs), autologous dendritic cells (DCs)…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Promising new combo therapy targets Hard-to-Treat lymphoma
Disease control OngoingPart 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To char…
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Zapping tumors with precision radiation may help control limited metastatic breast cancer
Disease control CompletedThis randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited …
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer drug targets BRCA mutations beyond breast and ovarian
Disease control OngoingThis phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug shows promise for Tough-to-Treat bone cancers
Disease control OngoingThis phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC